EPIGENOMICS AG Inactive Instrument
Epigenomics AG Stock Xetra
Equities
DE000A1K0516
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Sales 2022 | 485K 529K | Sales 2023 | 339K 370K | Capitalization | 1.59M 1.73M |
|---|---|---|---|---|---|
| Net income 2022 | -12M -13.1M | Net income 2023 | -4M -4.37M | EV / Sales 2022 | -5.22 x |
| Net cash position 2022 | 9.28M 10.13M | Net Debt 2023 | 9.78M 10.68M | EV / Sales 2023 | 33.5 x |
| P/E ratio 2022 |
-0.56
x | P/E ratio 2023 |
-0.36
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-09-29
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -36.69% | 8.55B | |
| +14.82% | 3.8B | |
| +7.01% | 2.44B | |
| -25.96% | 1.87B | |
| -16.67% | 1.74B | |
| +37.40% | 1.19B | |
| +32.75% | 830M | |
| -7.64% | 711M | |
| -17.76% | 589M |
